Advertisement

Psychopharmaka

  • Martin J. Lohse
  • Bruno Müller-Oerlinghausen

Zusammenfassung

Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 15 Jahren auffällig verändert. Im Durchschnitt haben die Verordnungen der Antidepressiva in der letzten Dekade jährlich um 15% zugenommen. Dieser Anstieg war 2012 erstmals deutlich geringer ausgefallen und hat sich 2013 nochmals verringert. Insgesamt flacht sich der über viele Jahre lineare Anstieg der Psychopharmakaverordnungen jetzt deutlich ab. Das gilt auch für die Verordnungen von Psychostimulanzien, die in Deutschland ca. 165 000 Kinder und Jugendliche erhalten. Dagegen sind die Verordnungen der früher führenden Tranquillantien seit vielen Jahren rückläufig. Circa ein Drittel der Psychopharmakaverordnungen stammen von Allgemeinmedizinern.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aderhold V, Weinmann S, Hägele C, Heinz A (2014): Frontale Hirnvolumenminderung durch Antipsychotika? Nervenarzt. 2014 May 25. [Epub ahead of print]Google Scholar
  2. Allroggen M, Udvardi PT, Pleuer PL, Kölch M, Fegert JM, Ludolph AG (2010) Langzeiteffekte von Psychostimulanzien – Welche Auswirkungen sind uns aus prä-/klinischen Studien bekannt. Psychopharmakotherapie 17:125–131Google Scholar
  3. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596–601Google Scholar
  4. Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19–36PubMedGoogle Scholar
  5. Anonym (2003) Lithium-Therapie bei der manisch-depressiven Erkrankung: Immer noch der Standard? Arzneimittelbrief 37:49–51Google Scholar
  6. Anonym (2008) Kinder: Neuroleptikagebrauch steigt. Arzneitelegramm 39:69–70Google Scholar
  7. Anonym (2009) Psychopanacea? Prescrire Internat 18:5–3Google Scholar
  8. Anonym (2011) Monitoring unwanted effects of antispychotics. Drug Ther Bull 49:117–120Google Scholar
  9. Anonym (2013) Agomelatine: A review of its adverse effects. Prescrire Int 22:70–71Google Scholar
  10. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3:449–456PubMedCentralPubMedGoogle Scholar
  11. Arzneimittelkommission der deutschen Ärzteschaft (2004): Suizide und Suizidversuche unter Bupropion. Deutsches Ärzteblatt 101 : A 2139–2140Google Scholar
  12. Arzneimittelkommission der deutschen Ärzteschaft (2006) Hypersexualität unter Aripiprazol. Dtsch Ärztebl 103:A351–8Google Scholar
  13. Arzneimittelkommission der deutschen Ärzteschaft (2008): Stellenwert von Antidepressiva in der Depressionsbehandlung. Arzneiverordnung in der Praxis 35: 42–43Google Scholar
  14. Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2009): Arzneiverordnungen. 22. Auflage, Medizinische Medien Informations GmbH (MMI), Neu-IsenburgGoogle Scholar
  15. Arzneimittelkommission der deutschen Ärzteschaft (2011): Aus der UAW-Datenbank: Abhängigkeitspotenzial unter Pregabalin (Lyrica®). Dtsch Ärztebl 108: A 183Google Scholar
  16. Arzneimittelkommission der deutschen Ärzteschaft (2013): Vorlage zur Abgabe einer schriftlichen Stellungnahme zur Nutzenbewertung nach § 35a SGB V, Lisdexamfetamindimesilat, Nr. 186, A13-24, Version 1. 0, 29.08.2013. Internet: http://www.akdae.de/Stellungnahmen/AMNOG/A-Z/Lisdexamfetamindimesilat/index.html
  17. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71:103–108PubMedGoogle Scholar
  18. Bachmann CJ, Lempp T, Glaeske G, Hoffmann F (2014) Antipsychotika-Verordnungen bei Kindern und Jugendlichen: Auswertung von Daten einer gesetzlichen Krankenkasse für den Zeitraum 2005–2012. Dtsch Arztebl 111:25–34Google Scholar
  19. Baghai TC, Lieb M, Möller HJ, Bschor T, Härter M, Schauenburg H (2011) Antidepressiva bei leichten depressiven Störungen. Psychiatr Prax 38:270–273PubMedGoogle Scholar
  20. Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R, Lewitzka U (2010) Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. NeuropsychoBiology 62:36–42PubMedGoogle Scholar
  21. Bauer M, Grof P, Müller-Oerlinghausen B (Hsgb.) (2006): Lithium in Neuropsychiatry: The Comprehensive Guide. Informa healthcare. Oxon (UK)Google Scholar
  22. Bschor T, Adli M (2009): Therapie depressiver Erkrankungen. Dtsch Ärztebl 105: A 782–A 792Google Scholar
  23. Bschor T, Hartung HD (2008) Antidepressiva Kombinationsbehandlungen. In Bschor T (Hsgb): Behandlungsmanual therapieresistenter Depressionen. Kohlhammer, Stuttgart, S, pp 86–101Google Scholar
  24. Bschor T, Müller-Oerlinghausen B (2014): Antidepressiva verringern nicht das Risiko von Suiziden oder Suizidversuchen bei depressiven Patienten Eine Entgegnung zurGoogle Scholar
  25. Presseerklärung der Deutschen Gesellschaft für Psychiatrie, Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). Arzneiverordnung in der Praxis 41: Heft 2, 2–4Google Scholar
  26. Bschor T, Müller-Oerlinghausen B, Stoppe G, Hiemke C (2014): New facts of long-term prophylaxis for bipolar affective disorder.] Nervenarzt. 2014 Jun 20. [Epub ahead of print]Google Scholar
  27. Carlson GA, Potegal M, Margulies D, Basile J, Gutkovich Z (2010) Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. Bipolar Disord 12:205–212PubMedCentralPubMedGoogle Scholar
  28. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 373:746–758Google Scholar
  29. Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C (2012) Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012 Oct 17;10:CD00653–3Google Scholar
  30. Cipriani A, Pretty H, Hawton K, Geddes JR (2005) Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162:1805–1819PubMedGoogle Scholar
  31. Cipriani A, Rendell J, Geddes JR (2010) Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24:1729–1738PubMedGoogle Scholar
  32. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28:75–84PubMedGoogle Scholar
  33. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L (2013) European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 23:1208–1218PubMedGoogle Scholar
  34. Collins JC, McFarland BH (2008) Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord 107:23–28PubMedGoogle Scholar
  35. Connolly KR, Thase ME (2011) If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71:43–64PubMedGoogle Scholar
  36. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O’Duffy A, Connell FA, Ray WA (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365:1896–1904PubMedGoogle Scholar
  37. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343:d455–1. doi: 10.1136/bmj.d4551Google Scholar
  38. Croissant B, Mann K (2004) Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit. Psychoneuro 30:30–36Google Scholar
  39. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS (2009) Cognitive effects of antipsychotic drugs in first-episode chizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166:675–682PubMedGoogle Scholar
  40. Dersch R, Zwernemann S, Voderholzer U (2011) Partial status epilepticus after electroconvulsive therapy and medical treatment with bupropion. Pharmacopsychiatry 44:344–346PubMedGoogle Scholar
  41. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (2009): S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression. Internet: media.dgppn.de/mediadb/media/dgppn/pdf/leitlinien/s3-nvl-unipolare-depression-lf.pdfGoogle Scholar
  42. Deutsche Gesellschaft für Soziale Psychiatrie (DGSP) (2009) DGSP-Memorandum zur Anwendung von Antipsychotika. Soziale Psychiatrie 34:50–51Google Scholar
  43. De Zwaan M, Gruss B, Müller A, Graap H, Martin A, Glaesmer H, Hilbert A, Philipsen A (2012) The estimated prevalence and correlates of adult ADHD in a German community sample. Eur Arch Psychiatry Clin Neurosci 262:79–86PubMedGoogle Scholar
  44. Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D (2013) Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs 27:1081–1092PubMedCentralPubMedGoogle Scholar
  45. Dolder CR, Nelson M, Snider M (2008) Agomelatine treatment of major depressive disorder. Ann Pharmacother 42:1822–1831PubMedGoogle Scholar
  46. Food andDAdministration(FDA) (2007): FDA proposes new warnings about suicidal thinking, behaviour in young adults to take antidepressant medications. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html.
  47. Fountoulakis KN, Möller HJ (2010) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14:405–412PubMedGoogle Scholar
  48. Friedmann PD (2013) Alcohol use in adults. N Engl J Med 368:1655–1656PubMedGoogle Scholar
  49. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM (2000) The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61:9–15PubMedGoogle Scholar
  50. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia (2007) Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68:1763–1774PubMedGoogle Scholar
  51. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN (2008) Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Int Med 149:734–750PubMedGoogle Scholar
  52. Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321:1371–1376PubMedCentralPubMedGoogle Scholar
  53. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library – Issue 1Google Scholar
  54. Gemeinsamer B (2010): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie:Google Scholar
  55. Anlage III Nummer 44 Stimulantien Vom 16. September 2010. Internet: www.g-ba.de/downloads/39-261-1185/2010-09-16_AM-RL3_Stimulantien_BAnz.pdfGoogle Scholar
  56. Gentile S (2007) Atypical antipsychotics for the treatment of bipolar disorders. CNS Drugs 21:367–387PubMedGoogle Scholar
  57. Gibbons RD, Brown CH, Hur K, Marcus SM, Baumikh DK, Erkenmann JJ (2007) Early evidence on the effects of regulators' suicidality warnings on prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356–1363PubMedGoogle Scholar
  58. Goldberg TE, Gomar JJ (2009) Targeting cognition in schizophrenia research: from etiology to treatment. Am J Psychiatry 166:631–634PubMedGoogle Scholar
  59. Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, Baldessarini RJ (2006) Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 8:618–624PubMedGoogle Scholar
  60. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290:1467–1473PubMedGoogle Scholar
  61. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65:432–441PubMedGoogle Scholar
  62. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992–1001PubMedGoogle Scholar
  63. Greil W, Häberle A, Haueis P, Grohmann R, Russmann S (2012) Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. Affect Disord 136:534–1542Google Scholar
  64. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1996) Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40:179–190PubMedGoogle Scholar
  65. Grof P (2013) Melancholia: a distinct entity? Can J Psychiatry 58:181–182PubMedGoogle Scholar
  66. Grof P, Müller-Oerlinghausen B (2009) A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord 11(Suppl 2):10–19PubMedGoogle Scholar
  67. Grohmann R, Engel RR, Geissler KH, Rüther E (2004): Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37 Suppl 1: S27–38Google Scholar
  68. Grund T, Lehmann K, Bock N, Rothenberger A, Teuchert-Noodt G (2006) Influence of methylphenidate on brain development–an update of recent animal experiments. Behav Brain Funct 10:2Google Scholar
  69. Hach I, Rentsch A, Krappweis J, Kirch W (2004) Psychopharmakaverordnungen an älteren Patienten. Z Gerontol Geriatr 37:214–220PubMedGoogle Scholar
  70. Hägg S, Bate A, Stahl M, Spigset O (2008) Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 31:685–694PubMedGoogle Scholar
  71. Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, Lohr K (2008) Metaanalysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 59:1121–1130PubMedCentralPubMedGoogle Scholar
  72. Healy D (2003) Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72:71–79PubMedGoogle Scholar
  73. Healy D (2006a) The latest mania: selling bipolar disorders. PLoS Med 3:e18–5Google Scholar
  74. Healy D (2006b) Did regulators fail over selective serotonin reuptake inhibitors? BMJ 333:92–95Google Scholar
  75. Hegerl U, Mergl R, Quail D, Schneider E, Hundemer HP, Linden M (2012) Does pain improve earlier than mood in depressed patients with painful physical symptoms treated with duloxetine? Pharmacopsychiatry 45:114–118PubMedGoogle Scholar
  76. Hjern A, Weitoft GR, Lindblad F (2010) Social adversity predicts ADHD-medication in school children – a national cohort study. Acta Paediatr 99:920–924PubMedGoogle Scholar
  77. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IWiG) (2009): Selektive Serotonin- und Noradrenalin-Wiederaufnahmehemmer (SNRI) bei Patienten mit Depressionen. Abschlussbericht A05-20A. Stand 17.06.2009. Internet: www.iqwig.de/download/A05-20A_Abschlussbericht_SNRI_bei_Patienten_mit_Depressionen.pdfGoogle Scholar
  78. Jans T, Warnke A (2010): Die britische NICE-Guidance zu Diagnose und Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. Arzneiverordnung in der Praxis. 37: 4–6Google Scholar
  79. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087PubMedGoogle Scholar
  80. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004) Efficacy and safety of antidepressants for children and adolescents. BMJ 328:879–883PubMedCentralPubMedGoogle Scholar
  81. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA (2006) The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163:813–821PubMedGoogle Scholar
  82. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. The Lancet 371:1085–1097Google Scholar
  83. Kasper S, Caraci F, Forti B, Drago F, Aguglia E (2010) Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol 20:747–765PubMedGoogle Scholar
  84. Kassenärztliche B (2006): Wirkstoff aktuell: Quetiapin (Seroquel®). Ausgabe 05/2006. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Quetiapin.pdf
  85. Kassenärztliche B (2008): Wirkstoff aktuell: Venlafaxin (Trevilor®). Ausgabe 03/2008. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Venlafaxin.pdf
  86. Kassenärztliche B (2010a: Wirkstoff Aktuell: Aripiprazol (Abilify®). Ausgabe 03/2010. Internet: http://www.akdae.de/Arzneimitteltherapie/WA/Archiv/Aripiprazol.pdf
  87. Kassenärztliche B (2010b: Agomelatin. Wirkstoff aktuell, Ausgabe 05/2010 Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Agomelatin.pdf
  88. Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, Leese M, McCrone P, Harris T, Moore M, Byng R, Brown G, Barthel S, Mander H, Ring A, Kelly V, Wallace V, Gabbay M, Craig T, Mann A (2009): Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13: iii-iv, ix-xi, 1–159Google Scholar
  89. Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM (2005) Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 352:2515–2523PubMedCentralPubMedGoogle Scholar
  90. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. PloS Med 5:e4–5Google Scholar
  91. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S (2010) Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev 2010 Dec 8(12):CD00814–1Google Scholar
  92. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009 Oct 7(4):CD00656–9Google Scholar
  93. Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S (2012) Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol 15:449–457PubMedGoogle Scholar
  94. Kupfer DJ, Frank E, Phillips ML (2012) Major depressive disorder: new clinical, neurobiological, and treatment perspectives. The Lancet 379:1045–1055Google Scholar
  95. Landessozialgericht B-B (2011): Beschluss vom 6. Dezember 2011 in dem Rechtsstreit Lundbeck GmbH – Antragstellerin – gegen Spitzenverband Bund der Krankenkassen – Antragsgegnerin – Gemeinsamer Bundesausschuss, Unterausschuss „Arzneimittel“ – Beigeladener (Az.: L 1 KR 184/11 ER)Google Scholar
  96. La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M (2014) Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 46:201–208Google Scholar
  97. Lepping P, Sambhi RS, Whittington R, Lane S, Poole R (2011) Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 198:341–345PubMedGoogle Scholar
  98. Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B, Zoghlami A, Benda N, Walter H (2001) The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8:89–95PubMedGoogle Scholar
  99. Letmaier M, Painold A, Holl AK, Vergin H, Engel R, Konstantinidis A, Kasper S, Grohmann R (2011) Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol 22:1–10Google Scholar
  100. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009a) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429–447Google Scholar
  101. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009b) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet 373:31–41Google Scholar
  102. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. The Lancet 361:1581–1589Google Scholar
  103. Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B (2013): Suizidprophylaktische Wirkung von Lithium. Aktueller Forschungsstand und Implikationen für die Therapie affektiver Störungen Nervenarzt 84: 294–306Google Scholar
  104. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1233PubMedGoogle Scholar
  105. Linde K, Berner M, Egger M, Mulrow C (2005) St John's wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry 186:99–107PubMedGoogle Scholar
  106. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2003) Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326:1014–1019PubMedCentralPubMedGoogle Scholar
  107. Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated SoftwareGoogle Scholar
  108. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011) Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306:1359–1369PubMedGoogle Scholar
  109. Maher AR, Theodore G (2012): Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 18 (5 Suppl B): S1–20Google Scholar
  110. McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010): Drug Class Review: Atypical Antipsychotic Drugs. Final Update 3 Report. Portland (OR): Oregon Health & Science University; July 2010. Internet: http://www.ncbi.nlm.nih.gov/books/NBK50583/
  111. McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS,Google Scholar
  112. Buckley PF, Wilkins TM, Stroup TS (2014) Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311:1978–1987PubMedCentralPubMedGoogle Scholar
  113. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610PubMedGoogle Scholar
  114. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012) Lithium toxicity profile: a systematic review and meta-analysis. The Lancet 379:721–728Google Scholar
  115. Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I (2009) Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12:1137–1147PubMedGoogle Scholar
  116. Mitchell AJ, Vaze A, Rao S (2009) Clinical diagnosis of depression in primary care: a meta-analysis. The Lancet 374:609–619Google Scholar
  117. Miyamoto S, Miyake S, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206–1227PubMedGoogle Scholar
  118. Molina BSG, Florey K, Hinshaw SP, Greiner, AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007) Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46:1028–1040PubMedGoogle Scholar
  119. Möller H-J, Volz HP, Reimann IW, Stoll KD (2001) Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21:59–65PubMedGoogle Scholar
  120. Moncrieff J (2008) Steht die Psychiatrie zum Verkauf an? Sozialpsychiatr Informationen 38:8–18Google Scholar
  121. Moncrieff J, Kirsch I (2005) Efficacy of antidepressants in adults. BMJ 331:155–157PubMedCentralPubMedGoogle Scholar
  122. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfron M (2007) National trends in the outpatient diagnosis and treatment of bipolar disorders in youths. Arch Gen Psychiatry 64:1032–1039PubMedGoogle Scholar
  123. Moret C, Isaac M, Briley M (2009) Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 23:967–974PubMedGoogle Scholar
  124. MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56:1073–1086Google Scholar
  125. Müller-Oerlinghausen B (2011): Antidepressiva sind nur bei sehr schwerer Depression Placebo überlegen. Arzneiverordnung in der Praxis 39: 60–62Google Scholar
  126. Müller-Oerlinghausen B (2012) Sind atypische Antipsychotika Mittel erster Wahl bei bipolaren Störungen? Kontra. Nervenarzt 83:1191–1192PubMedGoogle Scholar
  127. National Institute of Health and Clinical Excellence (NICE) (2009): Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Clinical Practice Guideline Number 82 (March 2009). Internet: http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdfGoogle Scholar
  128. Offidani E, Fava GA, Tomba E, Baldessarini RJ (2013) Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 82:132–141PubMedGoogle Scholar
  129. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA, For The Cafe Investigators (2009) Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 111:9–16PubMedGoogle Scholar
  130. Pollock B, Forsyth C, Bies R (2009) The critical role of clinical pharmacology in geriatric psychopharmacology. Clin Pharmacol Ther 85:89–93PubMedGoogle Scholar
  131. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians (2008) Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:725–733PubMedGoogle Scholar
  132. Rani F, Murray ML, Byrne PJ, Wong IC (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002–1009PubMedGoogle Scholar
  133. Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360:225–235PubMedCentralPubMedGoogle Scholar
  134. Reeves RR, Ladner ME (2010) Antidepressant-induced suicidality: an update. CNS Neurosci Ther 16:227–234PubMedGoogle Scholar
  135. Remschmidt H, Global ADHD Working Group (2005) Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 14:127–137Google Scholar
  136. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group (2010) Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18:136–145PubMedCentralPubMedGoogle Scholar
  137. Rösner S, Leucht S, Lehert P, Soyka M (2008) Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22:11–23PubMedGoogle Scholar
  138. Royal College of Psychiatrists, British Psychological Society (2006): Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. Internet: http://guidance.nice.org.uk/CG1/guidance/pdf/ English
  139. Sass H, Soyka M, Mann K, Zieglgansberger W (1996) Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673–680PubMedGoogle Scholar
  140. Sayadipour A, Mago R, Kepler CK, Chambliss RB, Certa KM, Vaccaro AR, Albert TJ, Anderson DG (2012) Antidepressants and the risk of abnormal bleeding during spinal surgery: a case-control study. Eur Spine J 21:2070–2078PubMedCentralPubMedGoogle Scholar
  141. Schubert I; Köster I, Lehmkuhl G (2010) Prävalenzentwicklung von hyperkinetischen Störungen und Methylphenidatverordnungen: Analyse der Versichertenstichprobe AOK Hessen/KV Hessen zwischen 2000 und 2007. Dtsch Arztebl Int 107:615–621PubMedCentralPubMedGoogle Scholar
  142. Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S (2011) A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 123:247–265PubMedGoogle Scholar
  143. Siegmund-Schulze N (2012) Polypharmakotherapie im Alter: Weniger Medikamente sind oft mehr. Dtsch Ärztebl 109:A418–A420Google Scholar
  144. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420–1431PubMedGoogle Scholar
  145. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ 3rd, Zhang W, Davidson JR, Pollack MH (2008) Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 197:675–681Google Scholar
  146. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180:396–404PubMedGoogle Scholar
  147. Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P (2012) A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 45:100–107PubMedGoogle Scholar
  148. Spielmans GI (2008) Duloxetine does not relieve painful psychological symptoms in depression. A metaanalysis. Psychother Psychosom 77: 12–16 Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013): Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10(3):e100140–3Google Scholar
  149. Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ (2012) Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 73:812–820PubMedCentralPubMedGoogle Scholar
  150. Stip E (2000) Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J Psychiatry Neurosci 25:137–153PubMedCentralPubMedGoogle Scholar
  151. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611–622PubMedGoogle Scholar
  152. Stübner S, Grohmann R, von Strahlendorff I, Rüther E, Möller HJ, Müller-Oerlinghausen B, Engel R, Horvarth A, Greil W (2010) Suicidality as a rare advserse event of antidepressant medication. Report from the AMSP Multicenter Drug Surveillance Project. J Clin Psychiatry 71:1293–1307PubMedGoogle Scholar
  153. Svensson S, Mansfield PR (2004) Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom 73:10–16PubMedGoogle Scholar
  154. Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S (2006) Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 45:1304–1313PubMedGoogle Scholar
  155. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA (2008) What CATIE Found: Results From the Schizophrenia Trial. Psychiatr Serv 59:500–506PubMedGoogle Scholar
  156. Tandon R, Jibson MD (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28:9–26PubMedGoogle Scholar
  157. Taylor D, Paton C, Kapur S (2009): Prescribing Guidelines. 10. Auflage. Informa healthcare. LondonGoogle Scholar
  158. Thase ME (2003) Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 64(Suppl 2):3–7Google Scholar
  159. Thase ME, Entsuah R, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective reuptake inhibitors. Br J Psychiatry 178:234–241PubMedGoogle Scholar
  160. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008) Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31:7–20PubMedGoogle Scholar
  161. Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011) Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 8:e100043–4Google Scholar
  162. Tsapakis EM, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E (2012) The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2(7):156–169Google Scholar
  163. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant triuals and its influence on apparent efficacy. N Engl J Med 358:252–260PubMedGoogle Scholar
  164. Ujeyl M, Müller-Oerlinghausen B (2012) Antidepressiva zur Behandlung der Depression bei Palliativpatienten: Eine systematische Übersicht. Schmerz 26:523–536PubMedGoogle Scholar
  165. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C (2009) Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19:629–635PubMedGoogle Scholar
  166. Volz HP, Möller HJ, Reimann I, Stoll K (2000) Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychopharmacol 10:211–217PubMedGoogle Scholar
  167. Walder A, Greil W, Baumann P (2009) Drug-induced Pisa syndrome under quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 33:1286–1287PubMedGoogle Scholar
  168. Wang SM, Han C, Lee SJ, Patkar AA, Pae CU, Fleischhacker WW (2012) Paliperidone: a review of clinical trial data and clinical implications. Clin Drug Investig 32:497–512PubMedGoogle Scholar
  169. Weinmann S, Read J, Aderhold V (2009) Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113:1–11PubMedGoogle Scholar
  170. Wensel TM, Powe KW, Cates ME (2012) Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46:424–429PubMedGoogle Scholar
  171. Whitaker R (2010) Anatomy of an epidemic. Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America. Crown Publishing, New YorkGoogle Scholar
  172. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, Boddington E (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet 363:1341–1345Google Scholar
  173. Williams JW Jr, Mulrow CD, Chiquette E, Hitchcock NP, Aguilar C, Cornell J (2000) Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132:743–756PubMedGoogle Scholar
  174. Wolter DK (2009): Risiken von Antipsychotika im Alter, speziell bei Demenzen. Eine Übersicht. Z Gerontopsychol psychiatr 22: 17–56Google Scholar
  175. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004) Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 18:262–276PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Martin J. Lohse
    • 1
  • Bruno Müller-Oerlinghausen
    • 2
  1. 1.Institut für Pharmakologie und ToxikologieUniversität WürzburgWürzburg
  2. 2.Berlin

Personalised recommendations